{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:06:28Z","timestamp":1779271588958,"version":"3.51.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,6,15]],"date-time":"2012-06-15T00:00:00Z","timestamp":1339718400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s00213-012-2773-2","type":"journal-article","created":{"date-parts":[[2012,7,19]],"date-time":"2012-07-19T23:39:12Z","timestamp":1342741152000},"page":"441-449","source":"Crossref","is-referenced-by-count":34,"title":["Outcome definitions and clinical predictors influence pharmacogenetic associations between HTR3A gene polymorphisms and response to clozapine in patients with schizophrenia"],"prefix":"10.1007","volume":"224","author":[{"given":"A. P.","family":"Rajkumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Poonkuzhali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Kuruvilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. S.","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,6,15]]},"reference":[{"key":"2773_CR1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","volume":"162","author":"NC Andreasen","year":"2005","unstructured":"Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR (2005) Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162:441\u2013449","journal-title":"Am J Psychiatry"},{"key":"2773_CR2","unstructured":"APA (2000) Diagnostic and statistical manual of mental disorders\u2014fourth edition text revision (DSM-IV-TR). American Psychiatric Association, Washington, DC"},{"key":"2773_CR3","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/schbul\/sbn114","volume":"34","author":"MJ Arranz","year":"2008","unstructured":"Arranz MJ, Kapur S (2008) Pharmacogenetics in psychiatry: are we ready for widespread clinical use? Schizophr Bull 34:1130\u20131144","journal-title":"Schizophr Bull"},{"key":"2773_CR4","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/S0140-6736(00)02221-2","volume":"355","author":"MJ Arranz","year":"2000","unstructured":"Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M, Lesch KP, Meyer JF, Sham P, Collier DA, Murray RM, Kerwin RW (2000) Pharmacogenetic prediction of clozapine response. Lancet 355:1615\u20131616","journal-title":"Lancet"},{"key":"2773_CR5","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1093\/hmg\/11.20.2517","volume":"11","author":"VS Basile","year":"2002","unstructured":"Basile VS, Masellis M, Potkin SG, Kennedy JL (2002) Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum Mol Genet 11:2517\u20132530","journal-title":"Hum Mol Genet"},{"key":"2773_CR6","first-page":"1171","volume":"154","author":"JK Briskin","year":"1997","unstructured":"Briskin JK, Curtis JL (1997) Augmentation of clozapine therapy with ondansetron. Am J Psychiatry 154:1171","journal-title":"Am J Psychiatry"},{"key":"2773_CR7","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/oxfordjournals.schbul.a006901","volume":"27","author":"P Buckley","year":"2001","unstructured":"Buckley P, Miller A, Olsen J, Garver D, Miller DD, Csernansky J (2001) When symptoms persist: clozapine augmentation strategies. Schizophr Bull 27:615\u2013628","journal-title":"Schizophr Bull"},{"key":"2773_CR8","doi-asserted-by":"crossref","unstructured":"Burns T (2007) Evolution of outcome measures in schizophrenia. Br J Psychiatry Suppl 50:s1\u2013s6","DOI":"10.1192\/bjp.191.50.s1"},{"key":"2773_CR9","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1176\/ajp.154.9.1243","volume":"154","author":"RR Conley","year":"1997","unstructured":"Conley RR, Carpenter WT Jr, Tamminga CA (1997) Time to clozapine response in a standardized trial. Am J Psychiatry 154:1243\u20131247","journal-title":"Am J Psychiatry"},{"key":"2773_CR10","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/16941","volume":"397","author":"PA Davies","year":"1999","unstructured":"Davies PA, Pistis M, Hanna MC, Peters JA, Lambert JJ, Hales TG, Kirkness EF (1999) The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature 397:359\u2013363","journal-title":"Nature"},{"key":"2773_CR11","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.cll.2008.05.003","volume":"28","author":"J Leon de","year":"2008","unstructured":"de Leon J, Arranz MJ, Ruano G (2008) Pharmacogenetic testing in psychiatry: a review of features and clinical realities. Clin Lab Med 28:599\u2013617","journal-title":"Clin Lab Med"},{"key":"2773_CR12","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/01.pap.0000249958.96498.ce","volume":"14","author":"L Dratcu","year":"2007","unstructured":"Dratcu L, Grandison A, McKay G, Bamidele A, Vasudevan V (2007) Clozapine-resistant psychosis, smoking, and caffeine: managing the neglected effects of substances that our patients consume every day. Am J Ther 14:314\u2013318","journal-title":"Am J Ther"},{"key":"2773_CR13","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archpsyc.1976.01770060086012","volume":"33","author":"J Endicott","year":"1976","unstructured":"Endicott J, Spitzer RL, Fleiss JL, Cohen J (1976) The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 33:766\u2013771","journal-title":"Arch Gen Psychiatry"},{"key":"2773_CR14","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.berh.2009.03.003","volume":"23","author":"C Estellat","year":"2009","unstructured":"Estellat C, Torgerson DJ, Ravaud P (2009) How to perform a critical analysis of a randomised controlled trial. Best Pract Res Clin Rheumatol 23:291\u2013303","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2773_CR15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2288-2-8","volume":"2","author":"RJ Feise","year":"2002","unstructured":"Feise RJ (2002) Do multiple outcome measures require p-value adjustment? BMC Med Res Methodol 2:8","journal-title":"BMC Med Res Methodol"},{"key":"2773_CR16","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.psc.2007.04.004","volume":"30","author":"A Foster","year":"2007","unstructured":"Foster A, Miller DD, Buckley PF (2007) Pharmacogenetics and schizophrenia. Psychiatr Clin North Am 30:417\u2013435","journal-title":"Psychiatr Clin North Am"},{"key":"2773_CR17","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/aje\/155.5.478","volume":"155","author":"WJ Gauderman","year":"2002","unstructured":"Gauderman WJ (2002) Sample size requirements for association studies of gene-gene interaction. Am J Epidemiol 155:478\u2013484","journal-title":"Am J Epidemiol"},{"key":"2773_CR18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0920-9964(02)00205-0","volume":"58","author":"B Gutierrez","year":"2002","unstructured":"Gutierrez B, Arranz MJ, Huezo-Diaz P, Dempster D, Matthiasson P, Travis M, Munro J, Osborne S, Kerwin RW (2002) Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response. Schizophr Res 58:93\u201397","journal-title":"Schizophr Res"},{"key":"2773_CR19","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1176\/appi.ajp.157.6.975","volume":"157","author":"DC Henderson","year":"2000","unstructured":"Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC (2000) Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 157:975\u2013981","journal-title":"Am J Psychiatry"},{"key":"2773_CR20","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00023210-200620050-00004","volume":"20","author":"J Horacek","year":"2006","unstructured":"Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Hoschl C (2006) Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 20:389\u2013409","journal-title":"CNS Drugs"},{"key":"2773_CR21","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00213-005-2223-5","volume":"181","author":"R Hwang","year":"2005","unstructured":"Hwang R, Shinkai T, De Luca V, Muller DJ, Ni X, Macciardi F, Potkin S, Lieberman JA, Meltzer HY, Kennedy JL (2005) Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory\/intolerant populations. Psychopharmacology (Berl) 181:179\u2013187","journal-title":"Psychopharmacology (Berl)"},{"key":"2773_CR22","doi-asserted-by":"crossref","first-page":"6460","DOI":"10.1523\/JNEUROSCI.5261-04.2005","volume":"25","author":"T Iidaka","year":"2005","unstructured":"Iidaka T, Ozaki N, Matsumoto A, Nogawa J, Kinoshita Y, Suzuki T, Iwata N, Yamamoto Y, Okada T, Sadato N (2005) A variant C178T in the regulatory region of the serotonin receptor gene HTR3A modulates neural activation in the human amygdala. J Neurosci 25:6460\u20136466","journal-title":"J Neurosci"},{"key":"2773_CR23","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/aje\/kwj259","volume":"164","author":"JP Ioannidis","year":"2006","unstructured":"Ioannidis JP, Trikalinos TA, Khoury MJ (2006) Implications of small effect sizes of individual genetic variants on the design and interpretation of genetic association studies of complex diseases. Am J Epidemiol 164:609\u2013614","journal-title":"Am J Epidemiol"},{"key":"2773_CR24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0895-4356(94)90038-8","volume":"47","author":"KS Jacob","year":"1994","unstructured":"Jacob KS (1994) The quest for the etiology of mental disorders. J Clin Epidemiol 47:97\u201399","journal-title":"J Clin Epidemiol"},{"key":"2773_CR25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.neulet.2008.01.083","volume":"435","author":"X Ji","year":"2008","unstructured":"Ji X, Takahashi N, Saito S, Ishihara R, Maeno N, Inada T, Ozaki N (2008) Relationship between three serotonin receptor subtypes (HTR3A, HTR2A and HTR4) and treatment-resistant schizophrenia in the Japanese population. Neurosci Lett 435:95\u201398","journal-title":"Neurosci Lett"},{"key":"2773_CR26","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789\u2013796","journal-title":"Arch Gen Psychiatry"},{"key":"2773_CR27","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1176\/appi.ajp.162.3.433","volume":"162","author":"KS Kendler","year":"2005","unstructured":"Kendler KS (2005) Toward a philosophical structure for psychiatry. Am J Psychiatry 162:433\u2013440","journal-title":"Am J Psychiatry"},{"key":"2773_CR28","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1053\/j.gastro.2011.03.011","volume":"140","author":"LA Kilpatrick","year":"2011","unstructured":"Kilpatrick LA, Labus JS, Coveleskie K, Hammer C, Rappold G, Tillisch K, Bueller JA, Suyenobu B, Jarcho JM, McRoberts JA, Niesler B, Mayer EA (2011) The HTR3A polymorphism c. -42C>T is associated with amygdala responsiveness in patients with irritable bowel syndrome. Gastroenterology 140:1943\u20131951","journal-title":"Gastroenterology"},{"key":"2773_CR29","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1038\/sj.npp.1301325","volume":"32","author":"S Leucht","year":"2007","unstructured":"Leucht S, Davis JM, Engel RR, Kane JM, Wagenpfeil S (2007) Defining \u2018response\u2019 in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology 32:1903\u20131910","journal-title":"Neuropsychopharmacology"},{"key":"2773_CR30","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1176\/ajp.151.12.1744","volume":"151","author":"JA Lieberman","year":"1994","unstructured":"Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Bookstein P, Kane JM (1994) Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 151:1744\u20131752","journal-title":"Am J Psychiatry"},{"key":"2773_CR31","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2165\/00023210-200216050-00004","volume":"16","author":"D Mancama","year":"2002","unstructured":"Mancama D, Arranz MJ, Kerwin RW (2002) Genetic predictors of therapeutic response to clozapine: current status of research. CNS Drugs 16:317\u2013324","journal-title":"CNS Drugs"},{"key":"2773_CR32","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1001\/archpsyc.60.10.1017","volume":"60","author":"J Melke","year":"2003","unstructured":"Melke J, Westberg L, Nilsson S, Landen M, Soderstrom H, Baghaei F, Rosmond R, Holm G, Bjorntorp P, Nilsson LG, Adolfsson R, Eriksson E (2003) A polymorphism in the serotonin receptor 3A (HTR3A) gene and its association with harm avoidance in women. Arch Gen Psychiatry 60:1017\u20131023","journal-title":"Arch Gen Psychiatry"},{"key":"2773_CR33","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archpsyc.60.1.82","volume":"60","author":"HY Meltzer","year":"2003","unstructured":"Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S (2003) Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 60:82\u201391","journal-title":"Arch Gen Psychiatry"},{"key":"2773_CR34","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/gps.1610","volume":"21","author":"E Mioshi","year":"2006","unstructured":"Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR (2006) The Addenbrooke\u2019s Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry 21:1078\u20131085","journal-title":"Int J Geriatr Psychiatry"},{"key":"2773_CR35","unstructured":"NCBI-SNP (2011) Reference SNP cluster report: rs1062613 [Online]. National Library of Medicine (US). Available: http:\/\/www.ncbi.nlm.nih.gov\/projects\/SNP\/snp_ref.cgi?rs=1062613 . Accessed 28 Nov 2011"},{"key":"2773_CR36","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00008571-200108000-00002","volume":"11","author":"B Niesler","year":"2001","unstructured":"Niesler B, Flohr T, Nothen MM, Fischer C, Rietschel M, Franzek E, Albus M, Propping P, Rappold GA (2001) Association between the 5\u2032 UTR variant C178T of the serotonin receptor gene HTR3A and bipolar affective disorder. Pharmacogenetics 11:471\u2013475","journal-title":"Pharmacogenetics"},{"key":"2773_CR37","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","volume":"10","author":"JE Overall","year":"1962","unstructured":"Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10:799\u2013812","journal-title":"Psychol Rep"},{"key":"2773_CR38","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0277-9536(88)90397-8","volume":"26","author":"JW Pennebaker","year":"1988","unstructured":"Pennebaker JW, Susman JR (1988) Disclosure of traumas and psychosomatic processes. Soc Sci Med 26:327\u2013332","journal-title":"Soc Sci Med"},{"key":"2773_CR39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF02703682","volume":"27","author":"S Prasad","year":"2002","unstructured":"Prasad S, Semwal P, Deshpande S, Bhatia T, Nimgaonkar VL, Thelma BK (2002) Molecular genetics of schizophrenia: past, present and future. J Biosci 27:35\u201352","journal-title":"J Biosci"},{"key":"2773_CR40","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1086\/519795","volume":"81","author":"S Purcell","year":"2007","unstructured":"Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81:559\u2013575","journal-title":"Am J Hum Genet"},{"key":"2773_CR41","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.schres.2006.10.008","volume":"90","author":"J Rabinowitz","year":"2007","unstructured":"Rabinowitz J, Levine SZ, Brill N, Bromet EJ (2007) The premorbid adjustment scale structured interview (PAS-SI): preliminary findings. Schizophr Res 90:255\u2013257","journal-title":"Schizophr Res"},{"key":"2773_CR42","unstructured":"Rajkumar AP, Chitra C, Bhuvaneshwari S, Poonkuzhali B, Kuruvilla A, Jacob KS (2012) Clinical predictors of response to clozapine in patients with Treatment Resistant Schizophrenia. Psychopharmacol Bull 44 (in press)"},{"key":"2773_CR43","doi-asserted-by":"crossref","first-page":"e6715","DOI":"10.1371\/journal.pone.0006715","volume":"4","author":"G Rammes","year":"2009","unstructured":"Rammes G, Hosp C, Eisensamer B, Tanasic S, Nothdurfter C, Zieglgansberger W, Rupprecht R (2009) Identification of a domain which affects kinetics and antagonistic potency of clozapine at 5-HT3 receptors. PLoS One 4:e6715","journal-title":"PLoS One"},{"key":"2773_CR44","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2165\/00023210-200519100-00004","volume":"19","author":"G Remington","year":"2005","unstructured":"Remington G, Saha A, Chong SA, Shammi C (2005) Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 19:843\u2013872","journal-title":"CNS Drugs"},{"key":"2773_CR45","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/FPC.0b013e3283313296","volume":"19","author":"A Schuhmacher","year":"2009","unstructured":"Schuhmacher A, Mossner R, Quednow BB, Kuhn KU, Wagner M, Cvetanovska G, Rujescu D, Zill P, Moller HJ, Rietschel M, Franke P, Wolwer W, Gaebel W, Maier W (2009) Influence of 5-HT3 receptor subunit genes HTR3A, HTR3B, HTR3C, HTR3D and HTR3E on treatment response to antipsychotics in schizophrenia. Pharmacogenet Genomics 19:843\u2013851","journal-title":"Pharmacogenet Genomics"},{"key":"2773_CR46","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1345\/aph.1G396","volume":"40","author":"PF Schulte","year":"2006","unstructured":"Schulte PF (2006) Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. Ann Pharmacother 40:683\u2013688","journal-title":"Ann Pharmacother"},{"key":"2773_CR47","doi-asserted-by":"crossref","first-page":"254","DOI":"10.4103\/0019-5545.58289","volume":"51","author":"RK Solanki","year":"2009","unstructured":"Solanki RK, Singh P, Munshi D (2009) Current perspectives in the treatment of resistant schizophrenia. Indian J Psychiatry 51:254\u2013260","journal-title":"Indian J Psychiatry"},{"key":"2773_CR48","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/FPC.0b013e328337ce3e","volume":"20","author":"RP Souza","year":"2010","unstructured":"Souza RP, de Luca V, Meltzer HY, Lieberman JA, Kennedy JL (2010) Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia. Pharmacogenet Genomics 20:274\u2013276","journal-title":"Pharmacogenet Genomics"},{"key":"2773_CR49","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nature08186","volume":"460","author":"H Stefansson","year":"2009","unstructured":"Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, Werge T, Pietilainen OP, Mors O, Mortensen PB, Sigurdsson E, Gustafsson O, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Suvisaari J, Lonnqvist J, Paunio T, Borglum AD, Hartmann A, Fink-Jensen A, Nordentoft M, Hougaard D, Norgaard-Pedersen B, Bottcher Y, Olesen J, Breuer R, Moller HJ, Giegling I, Rasmussen HB, Timm S, Mattheisen M, Bitter I, Rethelyi JM, Magnusdottir BB, Sigmundsson T, Olason P, Masson G, Gulcher JR, Haraldsson M, Fossdal R, Thorgeirsson TE, Thorsteinsdottir U, Ruggeri M, Tosato S, Franke B, Strengman E, Kiemeney LA, Melle I, Djurovic S, Abramova L, Kaleda V, Sanjuan J, de Frutos R, Bramon E, Vassos E, Fraser G, Ettinger U, Picchioni M, Walker N, Toulopoulou T, Need AC, Ge D, Yoon JL, Shianna KV, Freimer NB, Cantor RM, Murray R, Kong A, Golimbet V, Carracedo A, Arango C, Costas J, Jonsson EG, Terenius L, Agartz I, Petursson H, Nothen MM, Rietschel M, Matthews PM, Muglia P, Peltonen L, St Clair D, Goldstein DB, Stefansson K, Collier DA (2009) Common variants conferring risk of schizophrenia. Nature 460:744\u2013747","journal-title":"Nature"},{"key":"2773_CR50","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.schres.2005.07.025","volume":"79","author":"R Tandon","year":"2005","unstructured":"Tandon R, Fleischhacker WW (2005) Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res 79:145\u2013155","journal-title":"Schizophr Res"},{"key":"2773_CR51","volume-title":"WHODAS II Disability Assessment Schedule: 12-item interviewer administered version","author":"WHO","year":"2001","unstructured":"WHO (2001) WHODAS II Disability Assessment Schedule: 12-item interviewer administered version. World Health Organization, Geneva"},{"key":"2773_CR52","first-page":"29","volume":"9","author":"C Wongsinsup","year":"2010","unstructured":"Wongsinsup C, Taesotikul W, Kaewvichit S, Sangsrijan S, Sangsrija S (2010) Determination of clozapine in human plasma by high-performance liquid chromatography with UV-Vis detector. CMU J Nat Sci 9:29\u201337","journal-title":"CMU J Nat Sci"},{"key":"2773_CR53","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1080\/00207450590957863","volume":"115","author":"AL Zhao","year":"2005","unstructured":"Zhao AL, Zhao JP, Zhang YH, Xue ZM, Chen JD, Chen XG (2005) Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine. Int J Neurosci 115:1539\u20131547","journal-title":"Int J Neurosci"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-012-2773-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-012-2773-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-012-2773-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,22]],"date-time":"2022-01-22T09:04:13Z","timestamp":1642842253000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-012-2773-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,15]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["2773"],"URL":"https:\/\/doi.org\/10.1007\/s00213-012-2773-2","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,15]]}}}